📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. (2016)

First Author: Fitzgerald N
Attributed to:  The UK Centre for Tobacco and Alcohol Studies (UKCTAS) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/add.13438

PubMed Identifier: 27262594

Publication URI: http://europepmc.org/abstract/MED/27262594

Type: Journal Article/Review

Volume: 111

Parent Publication: Addiction (Abingdon, England)

Issue: 8

ISSN: 0965-2140